Search | Clinical Trials Finder

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: PANCRECARB® (pancrelipase), Placebo; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions: NHS7108, Zenpep®; Drug
Lead sponsor: Aimmune Nestlé Health Science US R&D, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • Los Angeles, California • Orlando, Florida + 5 more

Conditions: Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions: CD34 Stem Cell Selection Therapy; Biological
Lead sponsor: Diane George; Other
Eligibility: Up to 40 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Exocrine Pancreatic Insufficiency (EPI)
Interventions: Pancrelipase, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 21 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Sitagliptin, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Pancreatitis, Pancreatectomy, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase delayed release capsule, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 23
States / cities: Scottsdale, Arizona • Bristol, Connecticut • Tampa, Florida + 20 more

Conditions: Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase Delayed Release; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more

Conditions: Feeding Tube
Interventions: PEG-J placement; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions: Not listed
Lead sponsor: Epic Research & Diagnostics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: End Stage Renal Disease, End Stage Liver Disease
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Not listed
Enrollment: 13,767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cystic Fibrosis, Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more

Conditions: Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions: Alefacept; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency
Interventions: placebo, repaglinide; Drug
Lead sponsor: Arbelaez, Ana Maria; Individual
Eligibility: 12 Years to 24 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: GlycosBio Nutritional Supplement + PERT placebo, Standard Nutritional Supplement + PERT; Dietary Supplement
Lead sponsor: GlycosBio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diarrhea, Exocrine Pancreatic Insufficiency, Abdominal Pain
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: ANG003 Dose A, ANG003 Dose B, Creon; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions: Adipose tissue biopsy; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Ultrase® MT12; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 15
States / cities: Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more

Conditions: Pancreatic Adenocarcinoma
Interventions: Pancrelipase; Drug
Lead sponsor: Andrew Hendifar, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions: Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: GLP-1, GIP; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Shwachman-Diamond Syndrome
Interventions: Oral Glucose Tolerance Test, Modified Oral Glucose Tolerance Test, Modified Mixed Meal Tolerance Test, Continuous Glucose Monitor, Food Diary, Medical History Questionnaires; Diagnostic Test · Other · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Fibrosing Colonopathy
Interventions: ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 0 Months to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 123
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more

Search by objective public record fields.

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Self-Propelled Versus Standard Percutaneous Endoscopic Gastrojejunostomy(PEG-J); RCT

Prognostic Indicators as Provided by the EPIC ClearView

Transplant Patient Registry of Liver, Kidney and/or Pancreas

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis

Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis

Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Adipose Tissue Function After Pancreas Transplantation

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Diabetes/ Endocrine Surveillance in SDS

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)